Gastroesophageal adenocarcinoma (GEA), which includes stomach, gastroesophageal junction, and esophageal cancers, remains one of the most challenging cancers to treat.
The pace of progress in oncology continues to accelerate, driven by a deeper understanding of tumor biology and increasingly precise therapeutic approaches. That momentum is particularly meaningful in rare cancers, where unmet need remains high and rigorous science has the potential to make a real difference for patients.
Nick shares his experience recognizing early signs of stomach cancer, navigating diagnosis, learning the importance of HER2 testing, and finding strength through treatment, family support, and hope for the future.
Discover how advancing HER2 science is reshaping cancer care. By deepening understanding of tumor complexity and leveraging biomarker-driven approaches, we are enabling more precise therapies and driving innovation to improve outcomes for patients with HER2-expressing cancers and other areas of high unmet need.